PTCT Q2 2021 Earnings — PTC Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTCTPTC Therapeutics, Inc.

$5B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$117M+55.1% YoY

Gross Profit

$109M93.7% margin

Operating Income

-$98M-84.4% margin

Net Income

-$118M-101.5% margin

EPS (Diluted)

$-1.68

QoQ Revenue Growth

-1.1%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$47M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$2.1B

Total Liabilities

$1.9B

Stockholders' Equity

$197M

Cash & Equivalents

$177M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$117M	$75M	+55.1%
Gross Profit	$109M	$70M	+56.3%
Operating Income	-$98M	-$187M	+47.4%
Net Income	-$118M	-$181M	+34.8%

Revenue Segments

Product

$103M100%